Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sodium Hypochlorite Inclusion In Antiseptic Drug TFM Sought By Alcavis

This article was originally published in The Tan Sheet

Executive Summary

Sodium hypochlorite .05% to .5% should be classified as safe and effective in the OTC Tentative Final Monograph for Healthcare Antiseptic Drug Products, Alcavis International says in a Feb. 20 citizen petition

You may also be interested in...



Triclosan Efficacy Studies Support “Significant” Antimicrobial Effect – Ciba

New in vitro and in vivo studies on triclosan "substantially augment" the evidence supporting Category I status for the antimicrobial ingredient, Ciba Specialty Chemicals maintains in a Feb. 11 citizen petition to FDA

Triclosan Antiseptic Category I Status Requested By CIBA

FDA should consider new safety data supporting Category I (safe and effective) status for triclosan in the OTC Tentative Final Monograph for Health Care Antiseptic Drug Products, CIBA Specialty Chemicals and an alliance of six triclosan manufacturers/marketers state in a Sept. 13 citizen petition.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel